Breakthrough Drug Offers Hope for Chronic Hepatitis B Patients
Scientists Find a Potential Cure for Chronic Hepatitis B
The New York Times
Image: The New York Times
Researchers have reported a potential cure for chronic hepatitis B, with 20% of patients achieving a functional cure using the drug bepirovirsen. This significant advancement in treatment could change the lives of over one million Americans living with the chronic infection.
- 01Bepirovirsen, developed by Ionis Pharmaceuticals and GlaxoSmithKline, made the hepatitis B virus undetectable in 20% of patients.
- 02The drug was tested on over 1,838 patients across 29 countries, showing promising results in two 24-week studies.
- 03Chronic hepatitis B can lead to serious complications such as cirrhosis and liver cancer, affecting over one million people in the U.S.
- 04The treatment is administered via weekly injections and helps the immune system to attack the virus.
- 05The FDA is expected to make a decision on the drug's approval by October 26.
Advertisement
In-Article Ad
A groundbreaking study has revealed that the new drug bepirovirsen can potentially cure chronic hepatitis B in 20% of treated patients, marking a significant advancement in treatment. Chronic hepatitis B, which affects over one million individuals in the United States, can lead to severe health issues like cirrhosis and liver cancer. Unlike traditional treatments that require lifelong antiviral therapy, bepirovirsen offers a functional cure by making the virus undetectable in patients. The drug, developed by Ionis Pharmaceuticals and GlaxoSmithKline, was tested in two extensive studies involving more than 1,838 patients across 29 countries. Results indicated that patients receiving bepirovirsen showed no detectable virus 48 weeks post-treatment, while those on placebo did not achieve any cure. Dr. Anna S. Lok from the University of Michigan described these findings as remarkable and a major step forward in hepatitis treatment. Ionis has submitted an application to the FDA for approval, with a decision anticipated by October 26.
Advertisement
In-Article Ad
The potential approval of bepirovirsen could transform the treatment landscape for chronic hepatitis B in the U.S., offering hope to over one million affected individuals.
Advertisement
In-Article Ad
Reader Poll
How do you feel about the recent advancements in hepatitis B treatment?
Connecting to poll...
More about Memorial Sloan Kettering Cancer Center
Read the original article
Visit the source for the complete story.